Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1996 |
Name | rectum adenocarcinoma |
Definition | A rectum cancer that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer rectum cancer rectum adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
APC Q1429fs BRAF N581S ERBB2 L755S | Fluorouracil + Leucovorin + Trastuzumab | rectum adenocarcinoma | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602329 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT00967655 | Phase II | Capecitabine + Panitumumab Irinotecan | Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer | Unknown status | USA | 0 |
NCT01206530 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Bevacizumab Hydroxychloroquine | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | Completed | USA | 0 |
NCT01282502 | Phase I | Midostaurin | Midostaurin (PKC412) for Locally Advanced Rectal Cancer | Completed | USA | 0 |
NCT01298570 | Phase II | Fluorouracil + Irinotecan + Leucovorin Regorafenib | Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer | Completed | USA | 1 |
NCT01442935 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | Active, not recruiting | 1 | |
NCT01471353 | Phase II | Capecitabine + Sorafenib | Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01516216 | Phase II | Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Study of Vitamin D in Untreated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01538680 | Phase III | Regorafenib | Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy | No longer available | USA | CAN | 23 |
NCT01571284 | Phase III | Aflibercept + Fluorouracil + Irinotecan + Leucovorin | Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen | Completed | USA | CAN | 21 |
NCT01634685 | Phase I | Bavituximab + Capecitabine | A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma | Completed | USA | 0 |
NCT01652482 | Phase II | Cetuximab Duligotuzumab Fluorouracil + Irinotecan + Leucovorin | A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | 9 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01814501 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | Unknown status | USA | 0 |
NCT01871571 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | Active, not recruiting | USA | 0 |
NCT01896856 | Phase Ib/II | Guadecitabine + Irinotecan Regorafenib | Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer | Completed | USA | 1 |
NCT01939223 | Phase III | Regorafenib | COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) | Terminated | USA | CAN | 12 |
NCT01949194 | Phase II | Regorafenib | Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers | Unknown status | CAN | 0 |
NCT02008383 | Phase I | Cabozantinib + Panitumumab | Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02045030 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin | Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer | Terminated | CAN | 0 |
NCT02046538 | Phase II | Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Aflibercept | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | Withdrawn | USA | 0 |
NCT02096354 | Phase II | Regorafenib | A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02119676 | Phase II | Regorafenib Ruxolitinib | Study of Ruxolitinib in Colorectal Cancer Patients | Terminated | USA | 7 |
NCT02138617 | Phase II | Leucovorin Bevacizumab Irinotecan Fluorouracil | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02164916 | Phase II | Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02178644 | Phase I | YIV-906 Capecitabine | Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer | Completed | USA | 0 |
NCT02195011 | Phase II | Regorafenib | Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases | Completed | USA | 0 |
NCT02287727 | Phase II | Regorafenib | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | Withdrawn | USA | 0 |
NCT02305758 | Phase II | Fluorouracil + Irinotecan + Leucovorin Bevacizumab Veliparib | Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | Completed | 0 | |
NCT02368886 | Phase II | Clobetasol + Regorafenib | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02393755 | Phase Ib/II | Capecitabine + Nintedanib | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02550743 | Phase I | Alpelisib + Capecitabine | BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study | Terminated | USA | 0 |
NCT02569645 | Phase II | Rosuvastatin | Rosuvastatin in the Treatment of Rectal Cancer | Recruiting | CAN | 0 |
NCT02575508 | Phase Ib/II | Fluorouracil + Infigratinib + Irinotecan + Oxaliplatin | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | Withdrawn | USA | 0 |
NCT02651415 | Phase II | Perindopril + Regorafenib | Phase II Study of Perindopril and Regorafenib in mCRC | Completed | CAN | 0 |
NCT02688712 | Phase II | Capecitabine + Galunisertib Fluorouracil + Galunisertib Galunisertib Fluorouracil Capecitabine | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | Recruiting | USA | 0 |
NCT02788279 | Phase III | Atezolizumab Atezolizumab + Cobimetinib Regorafenib | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma | Completed | USA | CAN | 9 |
NCT02921256 | Phase II | Veliparib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Capecitabine + Veliparib Capecitabine | Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | Active, not recruiting | USA | 1 |
NCT02935309 | Phase I | Capecitabine + Lenvatinib | Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02972034 | Phase I | MK-8353 + Pembrolizumab | Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) | Active, not recruiting | USA | CAN | 0 |
NCT02997228 | Phase III | Atezolizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT03043313 | Phase II | Trastuzumab + Tucatinib Tucatinib | Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer | Recruiting | USA | 4 |
NCT03053544 | Phase II | Metformin | Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer | Completed | CAN | 0 |
NCT03102047 | Phase II | Durvalumab | Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer | Recruiting | USA | 0 |
NCT03261947 | Phase II | TAK-931 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |
NCT03300544 | Phase I | Capecitabine + Fluorouracil + Oxaliplatin + Talimogene laherparepvec | Talimogene Laherparepvec, Capecitabine, and Chemoradiation Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | Recruiting | USA | 0 |
NCT03365882 | Phase II | Cetuximab + Irinotecan Pertuzumab + Trastuzumab | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Recruiting | USA | 1 |
NCT03368859 | Phase II | ABT-165 + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab | Terminated | USA | CAN | 4 |
NCT03436563 | Phase Ib/II | M7824 | M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability | Recruiting | USA | 0 |
NCT03592641 | Phase II | Savolitinib | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | Recruiting | USA | 0 |
NCT03692429 | Phase I | Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (alloSHRINK) | Recruiting | USA | 1 |
NCT03801915 | Phase II | MVT-5873 | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | Recruiting | USA | 0 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03866239 | Phase I | Atezolizumab + Obinutuzumab + RO6958688 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | Recruiting | USA | 3 |
NCT03948763 | Phase I | mRNA 5671 mRNA 5671 + Pembrolizumab | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Recruiting | USA | 5 |
NCT03992456 | Phase II | Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Recruiting | USA | 0 |
NCT04017650 | Phase Ib/II | Cetuximab + Encorafenib + Nivolumab | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT04044430 | Phase Ib/II | Binimetinib + Encorafenib + Nivolumab | Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT04109924 | Phase II | Bevacizumab + Irinotecan + Trifluridine-tipiracil hydrochloride | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | Recruiting | USA | 0 |
NCT04126733 | Phase II | Nivolumab + Regorafenib | Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) | Active, not recruiting | USA | 0 |
NCT04130854 | Phase II | APX005M | Phase II Randomized Multi-center Trial of Total Neoadjuvant Therapy With and Without CD40 Agonist, APX005M, for Locally Advanced Rectal Adenocarcinoma | Recruiting | USA | 0 |
NCT04158349 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer (IPOX-FOLFIRI) | Recruiting | USA | 0 |
NCT04165772 | Phase II | Dostarlimab + Fluorouracil Capecitabine + Dostarlimab | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Rectal Adenocarcinoma | Recruiting | USA | 0 |
NCT04169347 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab | FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer | Recruiting | USA | 0 |
NCT04357587 | Phase I | Capecitabine + Pembrolizumab | Safety and Feasibility of PD-1 Blockade in the Treatment of Rectal Cancer | Recruiting | USA | 0 |
NCT04362839 | Phase I | Ipilimumab + Nivolumab + Regorafenib | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT04479436 | Phase II | U3-1402 | A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer | Recruiting | USA | 7 |
NCT04495621 | Phase Ib/II | Cetuximab + CH5132799 | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01) | Recruiting | USA | 6 |
NCT04599140 | Phase Ib/II | Nivolumab + SX-682 SX-682 | SX-682 and Nivolumab for RAS Mutated Microsatellite Stable Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1) | Recruiting | USA | 0 |
NCT04607668 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Trilaciclib | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): (PRESERVE1) | Recruiting | USA | 1 |
NCT04616183 | Phase Ib/II | Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT04737187 | Phase III | Bevacizumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer (SUNLIGHT) | Recruiting | USA | 1 |